Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

ACIP ponders recommendation for Prevnar use in seniors.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2142. No abstract available.

PMID:
25580485
2.

The latest on PaxVax’ and Gotovax AB’s cholera vaccine candidates.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2142. No abstract available.

PMID:
25580484
3.

Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2141-2. No abstract available.

PMID:
25580483
4.

Letter from the editor.

Ellis R, Riedmann E.

Hum Vaccin Immunother. 2014;10(9):2513-4. doi: 10.4161/21645515.2014.977606. No abstract available.

5.

Letter from the editor.

Ellis RW, Riedmann EM.

Hum Vaccin Immunother. 2015;11(1):1-2. doi: 10.4161/hv.36805. Epub 2014 Nov 1. No abstract available.

6.

Agenus’ brain cancer vaccine doubles survival rate in GBM patients.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2139-40. doi: 10.4161/hv.36804. No abstract available.

7.

Letter from the editor.

Ellis RW, Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2137-8. doi: 10.4161/hv.36803. No abstract available.

8.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2014;10(7):1771-2. doi: 10.4161/hv.36240. No abstract available.

9.

Evolution of whooping cough bacterium may reduce vaccine effectiveness.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1430. No abstract available.

PMID:
25396233
10.

Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1430. No abstract available.

PMID:
25396232
11.

MERS vaccine is technically feasible, but is it commerically feasible?

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1429-30. No abstract available.

PMID:
25396231
12.

Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1428-9. No abstract available.

PMID:
25396230
13.

Combining the cancer vaccine DPX-Survivac with immune modulators.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1428. No abstract available.

PMID:
25396229
14.

FDA approves sublingual hay fever immunotherapeutic.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1428. No abstract available.

PMID:
25396228
15.

New glioblastoma vaccine: safe and immunogenic in phase 1.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1427. No abstract available.

PMID:
25396227
16.

Human vaccines & immunotherapeutics: News.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(5):1139-42. doi: 10.4161/hv.29344. No abstract available.

17.

Human Vaccines & Immunotherapeutics. Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2014;10(5):1137-8. doi: 10.4161/hv.29345. No abstract available.

18.

Sanofi Pasteur shows efficacy of its dengue vaccine in phase 3.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1427. doi: 10.4161/hv.32075. No abstract available.

19.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2014;10(6):1425-6. doi: 10.4161/hv.29939. No abstract available.

20.

Fingerprint sensors to track vaccination records in developing countries.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):255. No abstract available.

PMID:
24963523
21.

Vical initiates vaccine trials against HSV-2 and CMV.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):255. No abstract available.

PMID:
24963522
22.

Pneumococcal vaccination does not prevent myocardial infarction.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):254. No abstract available.

PMID:
24963521
23.

HPV 16/18 prevalence reduced 3 years following vaccine introduction.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):254. No abstract available.

PMID:
24963520
24.

Influenza vaccine effectiveness boosted by near-infrared laser light.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):253-4. No abstract available.

PMID:
24963519
25.

Influenza vaccines prevented over 6 million flu cases in the US.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):253. No abstract available.

PMID:
24963518
26.

Agenus cancer vaccine extends survival of GBM patients.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):252-3. No abstract available.

PMID:
24963517
27.

Recently approved pandemic and seasonal influenza vaccines.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):252. doi: 10.4161/hv.28444. No abstract available.

PMID:
24836385
28.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):245-6. doi: 10.4161/hv.28445. No abstract available.

PMID:
24836383
29.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2014;10(1):1-2. doi: 10.4161/hv.28050. No abstract available.

PMID:
24832715
30.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2014;10(4):813-4. Epub 2014 Apr 1. No abstract available.

31.

New developments in nanoparticle-based vaccination.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2502. No abstract available.

PMID:
24716209
32.

Herd immunity protects babies against whooping cough.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2501-2. No abstract available.

PMID:
24716208
33.

Phase 3: RTS,S almost halves malaria cases in young children.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2501. No abstract available.

PMID:
24716207
34.

WHO prequalifies Chinese-produced Japanese encephalitis vaccine.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2500-1. No abstract available.

PMID:
24716206
35.

Two-dose vaccination program shows positive impact on varicella incidence.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2500. No abstract available.

PMID:
24716205
36.

Influenza vaccination reduces risk of heart attack and stroke.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2500. No abstract available.

PMID:
24716204
37.

Chinese scientists develop bird flu vaccine.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2499. No abstract available.

PMID:
24716203
38.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2497-8. doi: 10.4161/hv.27312. No abstract available.

PMID:
24569384
39.

Two studies on optimal timing for measles vaccination.

Riedmann EM.

Hum Vaccin Immunother. 2013 Dec;9(12):2499. doi: 10.4161/hv.27467. Epub 2013 Dec 1. No abstract available.

PMID:
24322739
40.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Nov;9(11):2277-8. Epub 2013 Nov 5. No abstract available.

41.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Apr;9(4):721. doi: 10.4161/hv.24622. No abstract available.

42.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Oct;9(10):2033. doi: 10.4161/hv.26667. Epub 2013 Oct 1. No abstract available.

PMID:
24084476
43.

Human vaccines & immunotherapeutics: news.

Riedmann EM.

Hum Vaccin Immunother. 2013 Oct;9(10):2034-7. doi: 10.4161/hv.26556. Epub 2013 Oct 18.

PMID:
24056006
44.

Human vaccines & immunotherapeutics: news.

Riedmann EM.

Hum Vaccin Immunother. 2013 Sep;9(9):1827-30. doi: 10.4161/hv.26237. Epub 2013 Aug 21.

45.

Letter from the editor.

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Sep;9(9):1825-6. doi: 10.4161/hv.26410. Epub 2013 Sep 1. No abstract available.

46.

Visionary concept: printable vaccines.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1744. No abstract available.

PMID:
23980268
47.

Therapeutic vaccine for treatment of genital herpes enters phase 2.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1744. No abstract available.

PMID:
23980267
48.

Chinese biotech partnership brings first hepatitis E vaccine to the market.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1743-4. No abstract available.

PMID:
23980266
49.

Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1743. No abstract available.

PMID:
23980265
50.

Three MRSA vaccines in early clincial trials.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1742. No abstract available.

PMID:
23980264

Supplemental Content

Loading ...
Support Center